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Abstract
Recent evidence that insulin-like growth factor-1 (IGF-1) influences certain properties of H4IIE hepatoma cells
independent of insulin led us to examine whether H4IIE cells express IGF-1 receptors. Competitive binding experiments
demonstrated IGF-1, but not insulin or IGF-II, could compete with [125I]IGF-1. Chemical crosslinking detected a protein
with an apparent mass of 175 kDa and its identity as the IGF-1 receptor K-subunit was confirmed by Western blotting. The
apparent molecular mass of this protein decreased to 135 kDa following deglycosylation. Immunofluorescence microscopy
verified that both insulin and IGF-1 receptors were present, although measurement of IGF-1 receptor quantity revealed they
were less abundant than insulin receptors. Binding of IGF-1 was low in growing cells and higher in a quiescent cell
population. Scatchard analysis confirmed that receptor density was increased in non-growing H4IIE cells while there was no
apparent difference in receptor affinity. Western blot analysis and RT-PCR revealed that both protein and mRNA levels
were elevated as cell growth ceased. Interestingly, addition of insulin to quiescent H4IIE cells, which stimulates cell
proliferation, further increased IGF-1 receptor protein levels with a peak at 12^24 h. Distinct modes of regulating IGF-1
receptor expression are indicated. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Insulin-like growth factor-1 (IGF-1) exerts its di-
verse biological e¡ects by binding to speci¢c recep-
tors located on the cell surface. The IGF-1 receptor
is a heterotetramer arranged in an K2L2 con¢guration
held together by disul¢de bridges [1]. The ligand
binding domain is formed by the extracellular K-sub-
units and signals are conveyed into the cell via the
transmembrane domain of the L-subunit. Activation
of the tyrosine kinase domain located on the intra-
cellular portion of the L-subunit initiates the intra-
cellular signalling cascade that mediates the cellular
response to IGF-1. Due to a high degree of structur-
al similarity with the insulin receptor which results in
heterologous binding of insulin to the IGF-1 receptor
(and vice versa) [2], it has been di⁄cult to identify
the biological e¡ects mediated solely by the IGF-1
receptor. Thus, while insulin has been designated a
metabolic hormone and IGF-1 is considered a mito-
genic factor, crossreactivity with respect to receptor
occupancy has obscured these distinctions.
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Although the liver is the primary source for circu-
lating IGF-1, there is little evidence that IGF-1 in-
£uences either hepatic metabolism or growth. For
instance, hepatic regeneration following injury, an
event that would most likely be associated with a
mitogen such as IGF-1, is directed by insulin [3]. A
lack of IGF-1 receptors on hepatocytes would ex-
plain these observations, and an absence of these
receptors has been reported in several studies [2,4].
On the other hand, there are published reports indi-
cating that IGF-1 receptors, although in lesser num-
bers, are expressed by hepatocytes [5^7]. Not surpris-
ingly, a clear consensus has not yet been reached on
this issue.
This laboratory has used the H4IIE hepatoma cell
line [8] to examine the intracellular systems medi-
ating insulin-dependent cell growth [9,10]. Over the
course of our investigations, we have noted that
IGF-1, although ine¡ective as a mitogen, is capable
of stimulating several growth-associated processes
[11]. Reports that the parental Reuber H-35 hepato-
ma cell line lacks IGF-1 binding activity [12,13],
however, suggest that H4IIE cells might also be de-
¢cient of IGF-1 receptors. A comprehensive exami-
nation of H4IIE cells was conducted to determine
whether IGF-1 receptors are present. Our investiga-
tion revealed that IGF-1 receptors are expressed by
H4IIE cells, and that this expression is modulated
during changes in growth state and by insulin.
2. Materials and methods
2.1. Cell culture
Rat H4IIE hepatoma cells (American Type Cul-
ture Collection, CRL 1548) were maintained in K-
modi¢ed Eagle’s medium (K-MEM, Gibco-BRL)
containing 10% fetal bovine serum, 2 mM glutamine,
50 Wg/ml streptomycin and 50 Wg/ml penicillin. Qui-
escence was achieved by placing the cells into serum-
free medium for 72 h [10].
2.2. Ligand binding
H4IIE cells were plated on 12-well culture dishes
and placed into serum-free media when 60% con£u-
ency was reached. To measure ligand binding [14],
the media was removed, the cells were washed twice
with ice-cold PBS (150 mM NaCl, 10 mM KPO4 pH
7.5) and the original media was replaced with 0.25 ml
K-MEM containing 20 mM HEPES pH 7.4 and
0.01% bovine serum albumin. The competitor pep-
tide (insulin, IGF-II or IGF-1) was added prior to
addition of the radiolabeled ligand [125I]IGF-1
(80 000 cpm). The cells were incubated with continu-
ous slow agitation for 2 h at 4‡C. The cells were
subsequently washed three times with ice-cold PBS
and solubilized by incubating with 0.5 ml NaOH (0.3
M) for 30 min at ambient temperature. The samples
were transferred to vials and mixed with scintillation
cocktail (Aquasol, New England Nuclear) for radio-
isotopic detection. Non-speci¢c binding was meas-
ured in the presence of excess (10 WM) unlabeled
IGF-1.
2.3. A⁄nity labeling
H4IIE cells were incubated with [125I]IGF-1 (New
England Nuclear, 25 WCi/ml) as described for ligand
binding. The cells were rinsed twice with 1 ml ice-
cold PBS and placed into 0.25 ml K-MEM contain-
ing 20 mM HEPES pH 7.4 and lacking bovine serum
albumin. Disuccinimidyl suberate (DSS), freshly pre-
pared in DMSO, was added to a ¢nal concentration
of 0.5 mM [15]. The samples were maintained on ice
for 30 min. The cells were subsequently washed three
times with 1 ml PBS and scraped from the plates
using Cell Lifters (Costar). The cells were collected
by centrifugation (5 min, 3000Ug) and suspended in
25 Wl 2USDS/gel loading bu¡er (1Ubu¡er = 62.5
mM Tris-HCl pH 6.8, 1% SDS, 10% glycerol,
0.005% Bromophenol blue, 5% L-mercaptoethanol).
The samples were brie£y sonicated and 15 Wl loaded
onto a 7.5% polyacrylamide gel. The gel was dried
and exposed to Re£ection autoradiography ¢lm
(New England Nuclear) with one intensifying screen.
2.4. Western blotting
Cell extracts were prepared in 12-well dishes by
addition of 150 Wl 2USDS/gel loading bu¡er. The
samples were brie£y sonicated, centrifuged for 15
min at 12 000Ug and 25 Wl loaded onto 7.5% poly-
acrylamide gels. Electrophoresis was conducted at
constant current and the proteins transferred to
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PVDF membrane in 20% methanol, 25 mM Tris, 130
mM glycine. Membranes were treated for 60 min at
room temperature with blocking solution (3% BSA
in TBS-T (10 mM Tris-HCl pH 7.5, 0.1 M NaCl,
1 mM EDTA, 0.1% Tween 20)). Primary antibody
was added in fresh blocking solution and incubated
for 60 min at 37‡C. Membranes were subsequently
washed three times over 15 min with TBS-T and
incubated for an additional 60 min at 37‡C in block-
ing solution with secondary antibody (1:10 000 di-
luted anti-rabbit-HRP). HRP was detected using
the ECL chemiluminescent system (Amersham) after
washing the membranes ¢ve times over 30 min with
TBS-T. All antibodies were purchased from Santa
Cruz Biotechnology.
2.5. Immunocytochemistry
Quiescent cells, prepared on glass slides (Super-
frost Plus, Fisher Scienti¢c), were washed twice
with cold PBS and ¢xed for 10 min at 4‡C in 1%
paraformaldehyde solution [16]. The cells were sub-
sequently permeabilized by treatment for 8 min at
4‡C with 0.1% Triton X-100 (in PBS), rinsed thor-
oughly with PBS, and incubated for 30 min at am-
bient temperature with TBS-T containing 3% BSA.
Incubations of 30 min with primary and secondary
antibodies (diluted with 1% BSA in TBS-T) were
used to visualize the cells for £uorescence microscopy
as described in the ¢gure legend.
2.6. Protein deglycosylation
H4IIE cells were scraped from 150-mm culture
dishes in 3 ml PBS using Cell Lifters. Cells were
collected by centrifugation (5 min 2000Ug), and
the pellet suspended with 10 vols. PBS. A 100-Wl
aliquot of the cell suspension was heated for 2 min
at 100‡C and allowed to cool. From this sample, 10
Wl was removed and combined with 5 Wl 5% NP-40
and 15 Wl N-glycanase (200 U/ml peptide-N-glyco-
sidase F, Oxford Glycosciences), and this mixture
was then incubated at 37‡C for 18 h. The sample
was mixed with an equal volume of 2USDS/loading
bu¡er and analyzed by Western blot after electro-
phoresis in a 7.5% polyacrylamide gel.
2.7. Receptor quanti¢cation
H4IIE cells were harvested from 150-mm culture
dishes as described in the previous section and ex-
tracted with 2.5 pellet volumes of PBS containing
1% Triton X-100. Nuclei were removed by centrifu-
gation (10 000Ug, 15 min). Serial dilutions of the
supernatant were mixed with 2USDS/gel loading
bu¡er and applied to a 7.5% polyacrylamide gel.
Serial dilutions of the control peptide (used as anti-
gen to raise the antibody) were applied to the same
gel after the samples had migrated 50% of the dis-
tance through the gel. When completed, the samples
were transferred to PVDF membrane and relative
amounts of IGF-1 and insulin receptor L-subunits
in the cellular material were determined by Wes-
tern blotting using the intensity of the control pep-
tide for comparison. Protein concentration was
determined with the BCA protein assay system
(Pierce).
2.8. Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from adherent cells using
Trizol (Gibco-BRL) as described previously [17]. The
RNA precipitate was collected by centrifugation,
washed (70% ethanol) and dissolved in 25 Wl
RNase-free water. RNA concentration was estimated
by absorbance at OD260. Reverse transcription of
1 Wg of RNA was conducted according to the
protocol recommended for the GeneAmp kit (Perkin
Elmer-Cetus). For PCR, 25 ng sense and antisense
primers and 1.25 U Amplitaq Taq DNA polymerase
were added to each RT-reaction (50 Wl ¢nal volume).
Ampli¢cation was conducted over 35 cycles using a
three-step program (1 min at 95‡C, 1 min at 55‡C,
1 min at 72‡C) that was concluded with 7 min at
72‡C. Samples were analyzed by electrophoresis on
1.7% agarose gel and visualized with SYBR Green I
(Molecular Probes). Primers for the IGF-1 receptor
[18], GAPDH [16] and ribosomal protein L32 (for-
ward primer, CAGGGTGCGGAGAAGGTT; re-
verse primer, GCGTTGGGATTGGTGACT; based
on the sequence reported by Dudov and Perry [19])
were prepared using an Oligo1000 DNA Synthesizer
(Beckman).
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3. Results
Although liver contains receptors for IGF-1 as
demonstrated by both ligand binding and a⁄nity
crosslinking experiments [5,6], the Reuber H-35 hep-
atoma from which the H4IIE cell line was derived
apparently lacks IGF-1 receptors [12,13]. Since we
have observed that certain intracellular events are
stimulated by IGF-1 [11], and there have been no
reports either verifying or refuting the presence of
IGF-1 receptors on H4IIE cells, we investigated
this question directly using [125I]IGF-1 as a ligand.
Binding of IGF-1 to H4IIE cells was observed
under conditions previously de¢ned for ¢broblasts
and smooth muscle cells [14] which used low temper-
ature to minimize receptor internalization. Radiola-
beled IGF-1 was displaced by addition of unlabeled
IGF-1 indicating competition for binding sites (Fig.
1). Insulin, which has a lower binding a⁄nity for the
IGF-1 receptor, was unable to compete with the
IGF-1. IGF-II, on the other hand, competed with
the ligand, but only at higher concentration. These
results indicate that H4IIE cells have high a⁄nity
binding sites for IGF-1 on their plasma membranes.
Chemical crosslinking of [125I]IGF-1 to H4IIE cells
with DSS demonstrated this ligand was bound to a
protein of 175 kDa as determined by SDS-PAGE
under reducing conditions (Fig. 2). This more closely
approximates the 135 kDa molecular mass typically
reported for the IGF-1 receptor K-subunit than the
IGF-II receptor which migrates with an apparent
molecular mass of 250 kDa [2,20]. The binding spe-
ci¢city was veri¢ed by the ability of competitor IGF-
1 to reduce the labeling intensity, while insulin and
IGF-II were 10^100-fold less e¡ective in displacing
the label.
To establish that the labeled protein was indeed
the K-subunit of the IGF-1 receptor, H4IIE cell ex-
tracts were examined by Western blotting. It was
observed, using speci¢c antibodies that did not cross-
react with the corresponding insulin receptor sub-
units, that both the K-subunit and L-subunit of the
IGF-1 receptor were present (Fig. 3A,B). Further-
more, the apparent molecular mass of the K-subunit
was calculated as 170 kDa, closely matching the val-
ue observed in crosslinking experiments (Fig. 2). The
L-subunit migrated with a molecular mass of 95 kDa,
identical to published values [1]. Although the appa-
rent molecular mass of 175 kDa for the K-subunit
(Fig. 3A) is higher than the 135 kDa usually quoted,
variations in molecular mass have been detected pre-
viously and these di¡erences can be accounted for by
the degree of N-linked glycosylation [21]. To verify
that the IGF-1 receptor of H4IIE cells is similarly
modi¢ed, cells were incubated with glycosylase F to
remove N-linked polysaccharides. Western blot anal-
Fig. 2. Receptor crosslinking to IGF-1. [125I]IGF-1 was incu-
bated with the cells for 2 h in the presence or absence of unla-
beled insulin, IGF-II or IGF-1 (at the indicated concentrations)
and unbound label removed by washing with PBS. Crosslinking
agent, 0.5 mM DSS, was added in fresh binding bu¡er exclud-
ing bovine serum albumin. After 30 min on ice, the cells were
harvested and the proteins crosslinked to IGF-1 identi¢ed by
autoradiography after SDS-PAGE. The molecular mass of the
labeled protein was calculated using prestained markers (their
position is indicated on the left side) run simultaneously in an
adjacent lane. Duplicate experiments provided identical results.
Fig. 1. Competitive ligand binding of IGF-1 to H4IIE hepato-
ma cells. Quiescent H4IIE cells were incubated with [125I]IGF-1
for 2 h in the presence or absence of either unlabeled insulin,
IGF-II or IGF-1. The bound [125I]IGF-1 was quanti¢ed by
scintillation counting after extensive washing to remove un-
bound label. Each data point represents the mean þ S.E. of ex-
periments conducted in triplicate.
BBAMEM 77460 25-9-98
P. Zahradka et al. / Biochimica et Biophysica Acta 1375 (1998) 131^139134
ysis of the samples revealed that the molecular mass
of the K-subunit was reduced to approximately 135
kDa by this treatment (Fig. 3C).
Our results suggest H4IIE hepatomas express re-
ceptors for both IGF-1 and insulin. Immuno£uores-
cence microscopy veri¢ed that both IGF-1 and insu-
lin receptors can be detected using a combination of
both primary and secondary antibodies, but not with
either alone (Fig. 4A^D). Speci¢city of the individual
antibodies for either the IGF-1 or the insulin recep-
tor L-subunit was established by preincubating the
antibodies with blocking peptide, which resulted in
a signi¢cant reduction in intensity (Fig. 4E,F). While
this approach provided a direct visualization of the
receptors, it could not be used to infer relative
amounts. To compare insulin and IGF-1 receptor
numbers, the control (i.e. antigenic or blocking) pep-
tide was used as the vehicle to translate band inten-
sity on a Western blot to actual concentration. The
protocol that was employed (see Section 2) estab-
lished that 3.2 ng insulin receptor/mg protein was
present in a cell lysate which contained 0.55 ng
IGF-1 receptor/mg protein (Table 1). The relative
Table 1






Concentration 3.21 þ 0.27 0.55 þ 0.12
Quiescent H4IIE cells were harvested and extracted for SDS-
polyacrylamide gel electrophoresis. Control peptide was applied
to the same gel in adjacent wells once electrophoresis of the ini-
tial cell samples was half completed. The insulin and IGF-1 re-
ceptor analysis were conducted on separate gels. After transfer
to PVDF membrane, antibodies to the receptor L-subunit were
used to probe the membrane and the band intensities quanti¢ed
by scanning densitometry. The standard curve produced using
the control peptide (100 Wg/ml stock concentration) was used to
calculate the receptor concentration in each sample. The protein
concentration of the cell lysate was determined using the BCA
protein assay.
Fig. 3. Western blot analysis of IGF-1 receptors. (A) Lysates of
quiescent H4IIE cells were applied to 7.5% polyacrylamide gels
and after electrophoresis transferred to PVDF membrane. The
blot was probed with antibody speci¢c for the IGF-1 receptor
K-subunit (N-20 region). (B) The same sample was applied to a
10% polyacrylamide gel and, following transfer to PVDF mem-
brane, probed with antibody speci¢c for the L-subunit (C-20 re-
gion) as indicated. (C) Deglycosylation was conducted as de-
scribed in Section 2, and migration of the IGF-1 receptor K-
subunit was monitored by Western blot after electrophoresis in
10% polyacrylamide. The applicable prestained molecular mass
markers (Benchmark Protein Ladders, Gibco-BRL) are shown
in each panel.
Fig. 4. Immunocytochemical analysis of H4IIE hepatoma IGF-
1 and insulin receptors. Quiescent cells were ¢xed and stained
with antibodies (diluted 1:200 in TBS-T plus 1% BSA) speci¢c
for either insulin or IGF-1 receptor L-subunits followed by
anti-rabbit IgG conjugated to Cy3. (A) and (B) show the results
of staining in the absence of primary (A) or secondary (B) anti-
bodies, respectively. Staining for the insulin (C,E) and IGF-1
(D,F) receptors were conducted without (C,D) or with (E,F) a
20 min incubation in the presence of 250 Wg control peptide.
Each panel includes a single colony of H4IIE cells photo-
graphed with a 20U objective and 1.67U phototube.
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IGF-1 receptor density is thus 17% of the insulin
receptor density.
Considering the close relationship with H4IIE
cells, the lack of observable IGF-1 binding in Reuber
H-35 hepatomas [12,13] contrasts markedly with the
observations reported herein. We have previously
noted with the angiotensin type 2 receptor, however,
that receptor binding can vary in accordance with
growth state [22]. It is therefore plausible that our
experiments and those of Krett et al. [13] were con-
ducted under su⁄ciently di¡erent conditions that di-
vergent results were obtained. To address this issue,
the IGF-1 binding characteristics of growing and
quiescent H4IIE cells were compared. Ligand bind-
ing revealed that both growing and quiescent H4IIE
cells exhibited similar binding characteristics for
IGF-1 (Fig. 5), with cells under both conditions
yielding a binding constant (Kd) of between 3.5 and
4 nM (growing, 3.55 þ 0.39; quiescent, 3.93 þ 0.24).
In contrast, the receptor density of quiescent cells
(59 600 sites/cell) was signi¢cantly higher than that
observed for growing cells (21 400 sites/cell), based
on Bmax values of 197.9 þ 4.6 and 71.0 þ 3.8 pM/106
cells, respectively. While evidence for functional
IGF-1 receptors was obtained with both growing
and quiescent cells, an increase in IGF-1 receptor
expression by quiescent H4IIE cells was indicated.
To de¢ne the changes in IGF-1 binding more di-
rectly, as well as to establish that IGF-1 binding
resulted from an association with the IGF-1 receptor,
levels of IGF-1 receptor protein and mRNA were
measured. Western blot analysis using an antibody
speci¢c for the IGF-1 receptor L-subunit revealed
that receptor levels increased as cells entered a qui-
escent state (Fig. 6). A parallel rise in IGF-1 receptor
mRNA was detected by reverse transcriptase-PCR
ampli¢cation (Fig. 7). These results strongly support
the ligand binding data which indicate IGF-1 recep-
tor levels are higher in quiescent H4IIE cells.
Fig. 7. RT-PCR analysis of IGF-1 receptor mRNA levels in
H4IIE hepatoma cells. Total RNA was isolated from proliferat-
ing (G) H4IIE cells or cells that had been placed into serum-
free media for 24 (1), 48 (2) or 72 (3) h. The RNA was reverse
transcribed (lane C had no RNA added) and subsequently PCR
ampli¢ed using primers speci¢c for the IGF-1 receptor (IGF-
1R), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or
ribosomal protein L32 (r-prot) as described in Section 2. The
products were resolved by electrophoresis on 1.7% agarose gels
and visualized using SYBR Green I DNA stain. DNA size
markers (HaeIII digested PX174 DNA) are shown in lane M
and cover the range from 1353 to 194 nucleotides. Identical re-
sults were obtained in two independent experiments.
Fig. 5. IGF-1 binding characteristics of growing and quiescent
H4IIE cells. A Scatchard analysis of IGF-1 binding was made
using both proliferating and quiescent (72 h in serum-de¢cient
media) H4IIE cells. All values, means þ S.E. of triplicate bind-
ing experiments, were normalized to cell number which was de-
termined in two independent wells on each culture dish. Dupli-
cate experiments yielded the same results for Kd and Bmax. The
inset shows the saturation curve for these data.
Fig. 6. Western blot analysis of the IGF-1 receptor L-subunit.
Growing H4IIE cells or cells that had been placed into serum-
de¢cient media for 1, 2 or 3 days were harvested by addition of
SDS-gel loading bu¡er. Samples with equivalent protein con-
centration (15 Wg) were analyzed by Western blotting using an
antibody directed to the C-terminus of the IGF-1 receptor as
described in Section 2. (A) Results using the antibody directly.
(B) Results obtained when the antibody was preincubated for
30 min with blocking peptide. Two additional experiments pro-
duced the same result.
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Insulin modulates insulin and IGF-1 receptor ex-
pression in numerous systems where it does not have
a mitogenic e¡ect. In H4IIE hepatomas, however,
where insulin functions as a mitogen as well as a
metabolic hormone [10,23], it is di⁄cult to distin-
guish whether the changes in IGF-1 receptor levels
between proliferating and quiescent cells re£ect a
change in cell growth status or a growth-independent
action by insulin directly on IGF-1 receptor expres-
sion. To address these issues, IGF-1 receptor levels
were monitored by Western blot analysis over a 48-h
period following the addition of insulin to quiescent
H4IIE cells. This approach was selected because the
metabolic conversion from a gluconeogenic to a gly-
cogenic phenotype occurs in less than 6 h, as indi-
cated by the a reduction in PEPCK mRNA levels,
whereas approximately 12 h is required to reach S
phase [10]. These experiments showed that IGF-1
receptor levels remain unchanged over the ¢rst 6 h,
but they increased approximately 4-fold by 12 h (Fig.
8). This increase is transient, however, since receptor
levels peak between 12 and 24 h and subsequently
decrease.
4. Discussion
Although the liver is the primary source for circu-
lating IGF-1, it remains unresolved whether IGF-1
in£uences hepatic function directly. This uncertainty
arises from contradictory evidence regarding the ex-
istence of IGF-1 receptors in the liver [21]. Also, it
has been established that insulin mediates hepatic
regeneration following injury [3]. Thus the distinction
typically observed in other tissues, where insulin op-
erates as a hormone to control cellular metabolism
while IGF-1 functions as a mitogen, is not apparent
in the liver.
Hepatic IGF-1 receptor density is highest in fetal
tissue [5,24]. In the adult liver, however, IGF-1 re-
ceptors have been detected by some investigators
[5,21], but not by others [2,4,6]. These con£icting
results may represent di¡erences in sensitivity related
to a speci¢c methodology, the source of the material
used for the experiments (i.e. intact cells or mem-
branes) or the animal species, and some of these
issues have been addressed by McEldu¡ et al. [21].
It is particularly noteworthy that IGF-1 receptors
were near the limits of detection even in those studies
demonstrating their presence [5] and an RNase pro-
tection study has con¢rmed that IGF-1 receptor
mRNA levels in adult liver are 94% lower than in
the fetal tissue [24]. On the other hand, it is evident
that IGF-1 receptor density increases signi¢cantly in
regenerating liver [5]. Correspondingly high levels of
IGF-1 receptors have also been observed on hepato-
ma cells which typically exhibit high rates of prolif-
eration [20,25,26]. Thus the developmental and
growth state of the tissue is an important factor in
IGF-1 receptor expression.
While IGF-1 apparently does not stimulate hepa-
tocyte proliferation following hepatectomy, it may
in£uence a restricted set of metabolic pathways asso-
ciated with glucose utilization in the liver [25,27,28].
These studies, however, were conducted with hepato-
ma cell lines, and their properties may not resemble
those of hepatocytes in many ways. For example,
only the H-35 and KRC7 hepatomas have been re-
ported to lack IGF-1 receptors and in this way re-
semble adult hepatocytes more closely [12,13,27]. In
contrast, other hepatoma lines, including the com-
monly used HepG2, BRL 3A and HTC hepatomas,
have an abundance of IGF-1 receptors [20,25,26].
The H4IIE hepatoma line has been well character-
ized with respect to insulin [8,23,29], but the response
of these cells to IGF-1 has received limited attention.
Our interest in this aspect was prompted by an ob-
Fig. 8. Modulation of IGF-1 receptor levels by insulin. Quies-
cent H4IIE cells (72 h in serum-de¢cient media) were stimulated
with 1 WM insulin and harvested at the indicated times by addi-
tion of SDS-gel loading bu¡er. Aliquots of 15 Wg protein were
analyzed by Western blot using an antibody to the IGF-1 re-
ceptor K-subunit. Band intensities from three independent ex-
periments (one example is provided as an inset) were quanti¢ed
by scanning densitometry and plotted as means þ S.E.
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servation that IGF-1 induced certain growth-associ-
ated processes, but was unable to stimulate DNA
synthesis ([11], Yau et al. manuscript in preparation).
Since H4IIE cells were derived in conjunction with
the Reuber H-35 hepatoma [8,30], it has been as-
sumed that they would exhibit similar characteristics.
In this study of H4IIE cells, however, we have dem-
onstrated that H4IIE cells express receptors for IGF-
1 (Figs. 1^4). Although the observed 175 kDa mo-
lecular mass is higher than the more accepted size of
135 kDa, the ability of IGF-1, but not insulin or
IGF-II, to e¡ectively compete for the ligand indicates
speci¢city for IGF-1. Furthermore, the di¡erence in
apparent molecular mass can be accounted for by the
degree of N-linked glycosylation (Fig. 3). Addition-
ally, we have observed that receptor density varies
with growth state (Fig. 5). Interestingly, while a sim-
ilar correlation between growth state and IGF-1 re-
ceptor density has been noted in studies comparing
fetal, adult and regenerating liver [5], the direction of
this change is reversed with respect to our ¢ndings.
Insulin receptor levels, on the other hand, have been
shown to increase in serum-starved HepG2 cells [31].
While some of the observed changes in receptor ex-
pression may re£ect the importance of IGF-1 to cell
cycle progression in other systems, additional studies
will be required to de¢ne the contribution of IGF-1
receptors to H4IIE cells.
Insulin functions as a negative regulator of insulin
receptor expression [31,32] and there is considerable
evidence that insulin may similarly control IGF-1
receptor expression [33]. For instance, IGF-1 recep-
tors were found to increase during fasting [34] and in
an experimental model of diabetes [35], and both
conditions are associated with low circulating insulin
concentrations. Furthermore, IGF-1 receptor levels
in diabetic rats were normalized by insulin treatment
[35]. Although our observations that IGF-1 receptor
protein and mRNA quantity is increased in quiescent
cells (Figs. 6 and 7) are diametrically opposite to the
previously mentioned studies, they may nevertheless
indicate that modulation of IGF-1 receptor expres-
sion is not a consequence of changes in growth state,
but rather of direct control by insulin [36]. This issue
was addressed by monitoring IGF-1 receptor levels
after adding insulin to quiescent H4IIE cells and the
increase in receptor amount (Fig. 8) clearly indicates
that IGF-1 receptor expression is enhanced by insu-
lin. Furthermore, no comparable change in insulin
receptor levels was detected upon probing the same
blots with an insulin receptor-speci¢c antibody (data
not shown). Therefore, the absence of insulin from
the culture media used to encourage entry into a
quiescent state may not be the primary mediator of
the increase in IGF-1 receptor numbers and, while
these observations do not conform with other pub-
lished reports on this topic [36], they do agree with
the ¢ndings of Hatada et al. [31] based on their study
of insulin receptor regulation.
The results presented in this report indicate that
IGF-1 receptors are present on H4IIE hepatoma cells
and that these proteins are inversely regulated by
growth state. Since insulin is the principal factor con-
trolling the growth of these cells, insulin may also
control IGF-1 gene expression directly. While a clear
distinction between a proliferation-mediated and an
insulin-mediated mechanism for the regulation of
IGF-1 receptors cannot be made, our experiments
suggest that these factors operate independently to
in£uence IGF-1 receptor levels.
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